Scientists Use High-Performance Computing to Understand Cancer Growth

A multi-institutional team of scientists is using Summit, America's fastest supercomputer for open science, to get a better understanding of how certain proteins signal body cells to reproduce uncontrollably, triggering cancer.
By |January 13th, 2021||0 Comments|

Sara Alert™ Academic Available for Universities to Help Monitor Individuals with COVID-19

As COVID-19 cases surge across the country, the university system is struggling to contain the spread of the disease and keep classes open. Sara AlertTM Academic is available now by subscription for university officials to securely automate the monitoring of students, faculty, and staff exposed to or infected with COVID-19 or any infectious disease.
By |November 17th, 2020||0 Comments|

ORISE Cytogenetic Biodosimetry Laboratory “Gamifies” Radiation Dose Estimation

The ORISE Cytogenetic Biodosimetry Laboratory (CBL) is the only federally funded facility with Clinical Laboratory Improvement Amendments certification in the United States that uses cytogenetic biodosimetry to assess absorbed radiation dose in exposed individuals. The ORISE Chromosome Challenge game applies crowdsourcing to scale-up the CBL’s ability to respond to mass-casualty incidents. Play the Chromosome Challenge game
By |November 17th, 2020||0 Comments|

X-Ray Study Explores Potential of Hepatitis C Drugs to Treat COVID-19

Experiments led by researchers at the Department of Energy’s Oak Ridge National Laboratory have determined that several hepatitis C drugs can inhibit the SARS-CoV-2 main protease, a crucial protein enzyme that enables the novel coronavirus to reproduce. Inhibiting, or blocking, this protease from functioning is vital to stopping the virus from spreading in patients with COVID-19. The study, published in the journal Structure, is part of efforts to quickly develop pharmaceutical treatments for COVID-19 by repurposing existing drugs known to effectively treat other viral diseases.
By |November 17th, 2020||0 Comments|

Collaborative Healthcare Model Created by BERG to Transform the Future of Drug Development

BERG, a clinical-stage biotech that employs artificial intelligence (AI) to investigate diseases and develop innovative treatments, announced a new collaborative model across the healthcare industry to fast track drug discovery research for COVID-19 and beyond. The new ecosystem comprised of BERG’s partners, such as Bristol Myers-Squibb, AdventHealth and the DOE-funded Oak Ridge National Lab, are identifying new ways of working and breaking down existing siloes to maximize time and efficiency in identifying and bringing new treatment options to market.
By |November 2nd, 2020||0 Comments|